Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 21, Issue 5, 2002, Pages 353-361

  Schurmann D ^a   Bergmann, F ^a   Albrecht, H ^b   Padberg, J ^a   Wunsche T ^a   Grunewald T ^c   Schurmann M ^a   Grobusch, M ^a   Vallee M ^a   Ruf, B ^c   Suttorp, N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Klinikum St Georg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FANSIDAR; FOLINIC ACID; IMMUNOGLOBULIN G ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLERGY; ANTIBODY DETECTION; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE CALCULATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERANCE; ENCEPHALITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PNEUMOCYSTIS CARINII; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; PROSPECTIVE STUDY; PROVOCATION TEST; STEVENS JOHNSON SYNDROME; SURVIVAL TIME; T LYMPHOCYTE; TIME; TOXOPLASMA;

EID: 0036327766     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-002-0723-3     Document Type: Article

References (67)

1. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus
2. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
3. Prophylaxis for toxoplasmosis in AIDS
4. Toxoplasmic encephalitis in AIDS
5. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens
6. Meta-analysis of prophylactic treatment against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients
7. Prophylaxis of Pneumocystis carinii infection in AIDS with pyrimethamine-sulfadoxine
8. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients
9. Pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus
10. Administration of pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients with AIDS
11. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS
12. Pyrimethamine and sulfadoxine as a preventive treatment for Pneumocystis carinii pneumonia and toxoplasma encephalitis
13. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS
14. Randomized trial of weekly sulfadoxine/pyrimethamine versus daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation
15. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
16. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
17. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
18. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease
19. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
20. Toxoplasmosis
21. Role of clindamycin in the treatment of acute toxoplasmosis of the central nervous system
22. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine
23. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
24. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients
25. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type I
26. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia
27. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
28. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis
29. Opportunistic infections
30. Toxoplasma gondii infection in advanced HIV infection
31. Risk factors for severe disease due to Toxoplasma gondii in HIV-positive patients
32. Extracerebral toxoplasmosis in AIDS. Histological and immunological findings based on 80 autopsy cases
33. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial
34. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex
35. Triple combinations: Present and future
36. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
37. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
38. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected patients with CD4 cell counts from 200 to 500 per cubic millimeter
39. Fansidar prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
40. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency immunodeficiency virus disease
41. Use of low-dose trimethorpim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients
42. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia
43. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia
44. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients
45. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: A prospective, randomized, controlled trial
46. Primary prophylaxis for Pneumocystis carinii pneumonia: A randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine
47. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus
48. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with HIV
49. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: A two-year Italian multicentric randomized controlled trial
50. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients
51. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV-infection who cannot tolerate trimethoprim, sulfonamides, or both
52. Prevention of Pneumocystis carinii pneumonia in AIDS patients with weekly dapsone
53. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
54. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death
55. Adverse reactions to pyrimethamine-sulfadoxine in context of AIDS
56. The safety of pyrimethamine and sulfadoxine for the prevention of Pneumocystis carinii pneumonia
57. Efficacy of sulfadoxine-pyrimethamine for the prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection
58. Adverse reactions associated with pyrimethamine-sulfadoxine prophylaxis for Pneumocystis carinii infections in AIDS
59. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis
60. Fansidar-associated fatal reaction in an HIV-infected man
61. Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus-infected person
62. How frequent are notified severe cutaneous adverse reactions to Fansidar?
63. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV-infection: Allergic or toxic?
64. Adverse reactions to pyrimethamine-sulfadoxine
65. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: Experience with 41 cases and a hypothesis regarding pathogenesis
66. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis
67. Practical issues in the management of hypersensitivity reactions: Sulfonamides